BL (N = 39) | M12 (N = 39) | M24 (N = 35) | |
---|---|---|---|
Women, n(%) | 25 (64.1) | 21 (60.0) | |
Men, n(%) | 14 (35.9) | 14 (40.0) | |
Age, years (IQR) | 56 (49–63) | 59 (51–56) | |
NSAIDs, n (%) | 27 (69.2) | 25 (64.1) | 21 (60.0) |
TNFi all, n (%) | 15 (38.5) | 16 (41.0) | 14 (40.0) |
TNFi in monotherapy | 4 (10.3) | 4 (10.3) | 3 (8.6) |
TNFi + csDMARD | 11 (28.2) | 12 (30.7) | 11 (31.4) |
Ustekinumab monotherapy, n (%) | 1 (2.6) | 0 | 0 |
Secukinumab monotherapy, n (%) | 0 | 1 (2.6) | 2 (5.7) |
csDMARD without biologic, n (%) | 17 (43.6) | 16 (41.0) | 14 (40.0) |
Methotrexate | 11 (28.2) | 11 (28.3) | 10 (28.6) |
Sulfasalazine | 2 (5.1) | 1 (2.6) | 1 (2.9) |
Apremilast | 1 (2.6) | 1 (2.6) | 2 (5.7) |
Methotrexate + Sulfasalazine | 3 (7.7) | 3 (7.7) | 1 (2.9) |
Prednisolone, n (%) | 3 (7.7) | 2 (5.1) | 2 (5.7) |
Anti-hypertensives, n (%) | 17 (43.6) | 14 (35.9) | 14 (40.0) |
Lipid lowering therapy, n (%) | 6 (15.4) | 5 (12.8) | 5 (14.3) |
Oral anti-diabetics, n (%) | 1 (2.6) | 2 (5.1) | 2 (5.7) |
Allopurinol, n (%) | 2 (5.1) | 2 (5.1) | 2 (5.7) |